Daxor Co. (NASDAQ:DXR) Short Interest Down 17.8% in March

by · The Cerbat Gem

Daxor Co. (NASDAQ:DXR – Get Free Report) saw a significant decrease in short interest in the month of March. As of March 31st, there was short interest totalling 10,600 shares, a decrease of 17.8% from the March 15th total of 12,900 shares. Currently, 0.5% of the company’s shares are short sold. Based on an average daily trading volume, of 7,100 shares, the days-to-cover ratio is presently 1.5 days.

Insider Activity

In other Daxor news, CEO Michael Richard Feldschuh acquired 3,360 shares of the company’s stock in a transaction dated Monday, March 10th. The shares were bought at an average cost of $7.68 per share, with a total value of $25,804.80. Following the purchase, the chief executive officer now directly owns 210,852 shares of the company’s stock, valued at $1,619,343.36. This trade represents a 1.62 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders bought 6,423 shares of company stock valued at $50,082 over the last quarter. 59.00% of the stock is owned by company insiders.

Hedge Funds Weigh In On Daxor

A hedge fund recently raised its stake in Daxor stock. Renaissance Technologies LLC raised its holdings in shares of Daxor Co. (NASDAQ:DXR – Free Report) by 87.7% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 27,821 shares of the company’s stock after acquiring an additional 13,000 shares during the quarter. Renaissance Technologies LLC owned about 0.57% of Daxor worth $214,000 as of its most recent filing with the Securities and Exchange Commission (SEC). Hedge funds and other institutional investors own 1.34% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, Ascendiant Capital Markets boosted their target price on shares of Daxor from $24.75 to $25.00 and gave the company a “buy” rating in a research report on Monday, March 17th.

Get Our Latest Analysis on DXR

Daxor Stock Up 7.7 %

Shares of DXR traded up $0.57 during trading hours on Monday, reaching $7.98. 3,272 shares of the stock traded hands, compared to its average volume of 6,785. The stock has a fifty day simple moving average of $7.72 and a 200 day simple moving average of $8.26. Daxor has a 52 week low of $6.55 and a 52 week high of $10.00.

About Daxor

(Get Free Report)

Daxor Corporation, a medical device company, provides blood volume measurement technology focused on blood volume testing. The company develops and markets BVA-100 Blood Volume Analyzer, a diagnostic blood test to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms for used in a broad range of medical and surgical conditions.

Further Reading